D M Asmuth

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens
    David M Asmuth
    University of California Davis Medical School, Sacramento, CA 95817, USA
    AIDS 26:1625-34. 2012
  2. ncbi Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques
    D M Asmuth
    Division of Infectious Diseases, Department of Internal Medicine, University of California Davis Medical Center, 4150 V Street, Sacramento, CA 95817, USA
    J Med Primatol 37:26-30. 2008
  3. ncbi Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
    David M Asmuth
    Division of Infectious Disease, Department of Internal Medicine, University of California at Davis, Sacramento, CA 95618, USA
    J Infect Dis 201:132-41. 2010
  4. ncbi Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial
    David M Asmuth
    Division of Infectious Diseases, University of California Davis Medical School, 4150 V Street, Sacramento, CA 95817 1460, USA
    J Infect Dis 201:1686-96. 2010
  5. ncbi Treatments for hepatitis B
    David M Asmuth
    Division of Infectious Diseases, Dept of Internal Medicine, UC Davis Medical Center, 4150 V St, PSSB G500, Sacramento, CA 95817, USA
    Clin Infect Dis 39:1353-62. 2004
  6. ncbi Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature
    R Rossero
    Department of Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, USA
    Int J STD AIDS 14:350-5. 2003
  7. ncbi Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection
    David M Asmuth
    Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA
    Antiviral Res 63:123-31. 2004
  8. ncbi Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection
    David M Asmuth
    Department of Internal Medicine, Division of Infectious Diseases and Immunology, University of California Davis Medical Center, 4150 V Street, Suite 6200 PSSB, Sacramento, CA 95817, USA
    Transfusion 43:451-8. 2003
  9. ncbi Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects
    Gail Skowron
    Division of Infectious Diseases, Roger Williams Medical Center, Providence, RI 02908, USA
    J Acquir Immune Defic Syndr 50:250-8. 2009
  10. ncbi Cell cycle kinetic dysregulation in HIV-infected normal lymphocytes
    David M Asmuth
    Department of Internal Medicine, University of California-Davis, Sacramento, California
    Cytometry A 66:41-51. 2005

Detail Information

Publications15

  1. ncbi Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens
    David M Asmuth
    University of California Davis Medical School, Sacramento, CA 95817, USA
    AIDS 26:1625-34. 2012
    ..To examine immune restoration in duodenal tissue and correlates of reduction of immune activation in chronic HIV-infected patients randomized to different treatment regimens...
  2. ncbi Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques
    D M Asmuth
    Division of Infectious Diseases, Department of Internal Medicine, University of California Davis Medical Center, 4150 V Street, Sacramento, CA 95817, USA
    J Med Primatol 37:26-30. 2008
    ..Limited investigations have explored the innate or adaptive immune responses of IFN-alpha on SIV replication in vivo...
  3. ncbi Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
    David M Asmuth
    Division of Infectious Disease, Department of Internal Medicine, University of California at Davis, Sacramento, CA 95618, USA
    J Infect Dis 201:132-41. 2010
    ..We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines...
  4. ncbi Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial
    David M Asmuth
    Division of Infectious Diseases, University of California Davis Medical School, 4150 V Street, Sacramento, CA 95817 1460, USA
    J Infect Dis 201:1686-96. 2010
    ..To our knowledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants with untreated human immunodeficiency virus type 1 (HIV-1) infection but without chronic hepatitis C virus (HCV) infection...
  5. ncbi Treatments for hepatitis B
    David M Asmuth
    Division of Infectious Diseases, Dept of Internal Medicine, UC Davis Medical Center, 4150 V St, PSSB G500, Sacramento, CA 95817, USA
    Clin Infect Dis 39:1353-62. 2004
    ..However, there remain many challenges in understanding the implications of drug resistance, the role of combination therapy, and how to define the response to therapy within subsets of patients with hepatitis B...
  6. ncbi Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature
    R Rossero
    Department of Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, USA
    Int J STD AIDS 14:350-5. 2003
    ..The results support the need for a randomized, prospective study to determine the safety and efficacy of hydroxyurea plus didanosine in antiretroviral-experienced patients with CD4(+) cell counts below 300 cells/mm(3)...
  7. ncbi Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection
    David M Asmuth
    Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA
    Antiviral Res 63:123-31. 2004
    ....
  8. ncbi Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection
    David M Asmuth
    Department of Internal Medicine, Division of Infectious Diseases and Immunology, University of California Davis Medical Center, 4150 V Street, Suite 6200 PSSB, Sacramento, CA 95817, USA
    Transfusion 43:451-8. 2003
    ....
  9. ncbi Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects
    Gail Skowron
    Division of Infectious Diseases, Roger Williams Medical Center, Providence, RI 02908, USA
    J Acquir Immune Defic Syndr 50:250-8. 2009
    ..To evaluate the association between baseline (BL) replication capacity (RC) (RCBL) and immunologic/virologic parameters (at BL and after 48 weeks on therapy) in HIV-1-infected subjects initiating antiretroviral therapy...
  10. ncbi Cell cycle kinetic dysregulation in HIV-infected normal lymphocytes
    David M Asmuth
    Department of Internal Medicine, University of California-Davis, Sacramento, California
    Cytometry A 66:41-51. 2005
    ..Prolonged S-phase durations in HIV-1 infected/p24(-) and G(0)/G(1)-phase durations in HIV-1 infected/p24(+) subpopulations require further study to identify mechanistic pathways...
  11. ncbi CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2
    David M Asmuth
    University of California Davis, Sacramento, CA, USA
    J Acquir Immune Defic Syndr 54:394-7. 2010
    ..To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients...
  12. ncbi Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection
    J William Critchfield
    Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616, USA
    J Virol 81:5460-71. 2007
    ..These findings demonstrate that rectal CD8(+) T cells are capable of robust and varied HIV-1-specific responses and therefore likely play an active role in eliminating infected cells during chronic infection...
  13. ncbi Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 42:426-34. 2006
    ..To assess the effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy (ART)...
  14. ncbi A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re
    Michael J Borucki
    University of Texas Health Center, Tyler, TX, USA
    Antiviral Res 64:103-11. 2004
    ....
  15. ncbi Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis
    W Lawrence Drew
    Mount Zion Medical Center, University of California, San Francisco, CA 94115, USA
    J Infect Dis 186:114-7. 2002
    ..These rates were similar among case patients and control subjects and were similar by risk group. The CMV gB2 genotype is not a major determinant of retinitis pathogenicity but appears to be highly prevalent among HIV-infected patients...